UPDATE 1-Lilly cancer drug improves survival, raises blood clot risk -FDA
July 07, 2015 at 09:38 AM EDT
WASHINGTON, July 7 (Reuters) - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots, according to a preliminary review by the U.S. Food and Drug Administration.